DIACOMIT (stiripentol) is an adjunctive therapy for the treatment of seizures in patients with Dravet syndrome who are also taking clobazam, providing effective seizure control in pediatric and adult patients.

Therapeutic Effect of DIACOMIT in Seizure Management for Dravet Syndrome

DIACOMIT, approved for use in patients with Dravet syndrome, targets the reduction of seizures when used in combination with clobazam. It is specifically indicated for patients who are 6 months of age or older, weigh at least 7 kg, and are already on clobazam therapy. The therapeutic effect of DIACOMIT has been shown to improve seizure frequency and control, particularly in pediatric patients. The drug’s efficacy is supported when used as adjunctive therapy and not as a monotherapy. However, it requires careful monitoring, especially for potential adverse effects like somnolence or decreased appetite, which may affect overall patient well-being. "Not specified in the description" for the direct mechanism of action or other comparative therapeutic effects.